Barinthus Biotherapeutics (BRNS) AI Stock Analysis

• Market Cap: $38.16M
• Dividend Yield: N/A
• Average Volume (3M): 30.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: 4413.19%
• EPS Growth: 10.56%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 40,339,394
• 10 Day Avg. Volume: 12,468
• 30 Day Avg. Volume: 30,879
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.25
• Enterprise Value/Revenue: -0.26
• Enterprise Value/Gross Profit: -0.64
• Enterprise Value/Ebitda: 0.04
• 1Y Price Target: $3.00
• Price Target Upside: 215.79% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 44 Neutral
• Price Target: $1.00 ▲(5.26%Upside)

The overall stock score is primarily driven by the financial performance challenges, including persistent net losses and negative cash flows, despite strong revenue growth. Technical indicators are neutral, but negative valuation metrics further weigh on the score. The company's strong cash reserves offer some mitigation against these risks.

Positive Factors

Analyst Rating

Analyst reiterates a Buy rating and a $3 price target on the stock.

Clinical Trials

VTP-300 data in chronic hepatitis B presented positive results from two Phase 2 trials, with some participants achieving functional cure and seroconversion.

Financial Stability

Cash runway into 2027 with $100.6M in cash and restricted cash, and management expects existing capital to fund operations into 2027.

Negative Factors

Financial Performance

Net loss was $19.6M, or ($0.49) per share, more than the estimated loss of $12.0M due to foreign exchange, asset depreciation and workforce reduction.

Probability of Approval

The probability of approval for VTP-300 has been reduced from 45% to 15%.

Regulatory Risks

Risks include failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.

Barinthus Biotherapeutics Business Overview & Revenue Model

Company Description

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

How the Company Makes Money

Barinthus Biotherapeutics makes money primarily through the commercialization of its proprietary therapeutic products. The company generates revenue by licensing its technology to pharmaceutical partners who help in the distribution and marketing of its products globally. Additionally, BRNS engages in strategic partnerships and collaborations with other biotech firms and research institutions, which often involve upfront payments, milestone payments, and royalties on product sales. The company may also secure funding through government grants and research contracts, supporting its continued innovation and development efforts.

Barinthus Biotherapeutics Financial Statement Overview

Summary

Barinthus Biotherapeutics is experiencing rapid revenue growth, with a 1766% increase, but faces profitability challenges due to consistent net losses and negative cash flow. Strong cash reserves offer some stability, yet financial risks persist.

Income Statement

Barinthus Biotherapeutics has faced significant challenges with consistent net losses over the years, including a net income loss of $61 million in the most recent year. However, the company showed a remarkable revenue growth from $802,000 to $14.97 million, reflecting a 1766% increase, which is a promising sign. Nevertheless, the negative EBIT and EBITDA margins indicate that profitability remains a significant concern.

Balance Sheet

The company maintains a strong cash position with $110.66 million in cash and equivalents, which is crucial for operations. However, the debt-to-equity ratio has risen to 0.09 from previous years, which is still manageable. The equity ratio has decreased, indicating declining shareholder equity relative to total assets, suggesting that financial stability could be at risk if losses continue.

Cash Flow

Operating cash flow remains negative at -$28.94 million, highlighting ongoing operational challenges. Free cash flow has improved from -$56.34 million to -$29.83 million, but this still signals cash management issues. The lack of positive cash flow presents a risk unless revenue growth translates to improved cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.80M	14.97M	802.00K	44.70M	268.00K	4.82M
Gross Profit	15.06M	9.17M	-4.64M	44.70M	268.00K	4.82M
EBITDA	-58.89M	-55.37M	-71.06M	6.40M	-47.87M	-14.03M
Net Income	-65.22M	-61.07M	-73.35M	5.34M	-50.87M	-17.71M
Balance Sheet
Total Assets	142.00M	160.33M	214.51M	270.20M	280.71M	50.67M
Cash, Cash Equivalents and Short-Term Investments	99.12M	110.66M	142.09M	194.38M	214.05M	43.27M
Total Debt	11.92M	12.01M	12.98M	8.77M	7.22M	46.36M
Total Liabilities	26.40M	30.19M	27.51M	27.00M	28.15M	87.58M
Stockholders Equity	115.49M	130.03M	186.78M	242.90M	252.13M	-37.30M
Cash Flow
Free Cash Flow	-25.74M	-29.83M	-56.34M	-20.57M	-33.73M	-11.32M
Operating Cash Flow	-27.54M	-28.94M	-50.92M	-14.43M	-32.58M	-11.03M
Investing Cash Flow	-589.33K	-892.00K	-5.41M	-5.75M	-12.91M	-293.00K
Financing Cash Flow	1.66M	2.16M	1.87M	325.00K	222.74M	41.44M

Barinthus Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Positive. The current price of 0.95 is above the 20-day moving average (MA) of 0.93, above the 50-day MA of 0.92, and below the 200-day MA of 1.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.73 is Neutral, neither overbought nor oversold. The STOCH value of 72.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRNS.

Barinthus Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	CHF22.87B	15.27	10.81%	2.12%	47.85%	-11.82%
ALGS	53 Neutral	$44.70M	―	-60.44%	―	-76.29%	―
BRNS	44 Neutral	$38.16M	―	-45.40%	―	4413.19%	10.56%
GDTC	41 Neutral	$26.63M	―	-24.97%	―	―	38.80%
BOLD	40 Underperform	$23.73M	―	-54.06%	―	―	―
CLGN	40 Underperform	$18.06M	―	-75.27%	―	-76.73%	-85.83%
ALXO	39 Underperform	$23.16M	―	-102.99%	―	―	30.37%

Barinthus Biotherapeutics Corporate Events

Barinthus Biotherapeutics Approves Key Proposals at AGM

On June 10, 2025, Barinthus Biotherapeutics held its Annual General Meeting where all proposed matters were approved, including the re-election of directors and the appointment of auditors. The meeting also covered financial matters such as the approval of the directors’ remuneration policy and the decision not to pay dividends for the fiscal year ending December 31, 2024.

The most recent analyst rating on (BRNS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.

Barinthus Biotherapeutics Restructures Leadership with New CFO

Barinthus Biotherapeutics announced significant corporate developments, including the termination of Gemma Brown as CFO as part of a restructuring plan, with William Enright assuming her financial responsibilities. The company presented promising data from its HBV003 and IM-PROVE II trials at the EASL Congress, highlighting the potential of VTP-300 in combination with other treatments for chronic hepatitis B. These developments are part of Barinthus Bio’s strategic focus on immunological and inflammatory diseases, aiming to strengthen its market positioning and support ongoing partnering efforts.